Replay of the virtual KOL event featuring Prof. Mohamad Mohty, MD, PhD (Saint-Antoine Hospital – AP-HP) and Dr. Monzr M. Al Malki, MD (City of Hope) where they discussed:
- Unmet medical needs in acute Graft-versus-Host Disease,
- The latest data on MaaT013 from the Early Access Program, as presented at the 2024 ASH Annual Meeting,
- The potential of microbiome immunomodulation in their clinical practice.
Dowload the presentation here.
Find below the video summary:
00:00 to 8:40 : Introduction by Hervé Affagard, CEO and co-founder of MaaT Pharma
8:41 to 14:55 : Unmet need for MaaT013 in GvHD in Europe and in the US with Dr. Monzr M. Al Malki M.D
14:56 to 26:00 : Results from the Early Access Program in Europe with Pr Mohamad Mohty, M.D
26:01 to 29:45 : Upcomming milestones for MaaT Pharma with Hervé Affagard
29:46 to 56:46 : Q&A session, with Pr Mohamad Mohty, M.D, Dr. Monzr M. Al Malki M.D, Hervé Affagard, and Gianfranco Pittari M.D. PhD, Chief Medical Officer of MaaT Pharma
